Dr Reddy’s Laboratories disclosed on Thursday that it will delay commercial supplies of its semaglutide product after identifying an issue related to the active pharmaceutical ingredient (API). The company said certain batches were found to be out of specification and that it is probing the root cause while implementing corrective actions to protect product quality.
The firm notified exchanges in a filing that commercial shipments will be postponed until the API-related problem is resolved. The notice did not include an expected timeframe for when normal supplies might resume.
Market reaction was immediate. Shares listed on the National Stock Exchange of India dropped as much as 6.5% to 1,261.10 rupees by 11:41 IST on Thursday following the announcement.
In its filing, the company emphasized that the API issue does not pose a patient safety concern and does not affect the product's existing global regulatory submissions. Management said it is taking corrective measures while investigating the cause of the out-of-specification batches.
Dr Reddy’s also scheduled a conference call later on Thursday to discuss the matter and to answer questions from investors and analysts. The call is intended to provide further detail on the company’s investigation and the remediation steps being pursued.
For market participants and stakeholders, the situation presents a set of immediate operational and market considerations. Supply timelines for the branded semaglutide product will be pushed back until the API issue has been identified and corrected. Meanwhile, equity investors faced an abrupt re-pricing of the company’s stock during trading on Thursday.
The filing and the subsequent conference call are the company’s primary channels for further updates. Until the investigation concludes and corrective actions are completed, the duration of the commercial supply interruption remains unspecified in the company communication.
Context for investors and industry observers
- Operational - Production and commercial supply schedules are paused for the affected product while quality investigations continue.
- Market - The company’s shares experienced a sharp intraday decline after the regulatory filing was made public.
- Regulatory and safety - The company stated the issue does not impact patient safety and does not alter the status of existing global regulatory filings.